Historically, the assessment of surgical outcomes in patients with glioma has been focused on technical outcomes, such as volumetric analysis of the residual tumour, progression-free survival, and overall survival. Other outcomes, such as neurological deficits, can be challenging to assess in an objective, quantifiable, and comprehensive manner. As a result, no consensus is available on methods to systematically evaluate perioperative…
[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment
The Lancet Oncology | | Jasper K W Gerritsen, Philipp Karschnia, Lorenzo Bello, Shawn Hervey-Jumper, Jacob S Young, Kathleen Seidel, Djaina D Satoer, Oliver Schnell, Michael Parsons, Brian V Nahed, Grazia Menna, Nico Teske, External Rater Panel, Timothy R Smith, Nader Sanai, Sandro M Krieg, Philippe Schucht, Marike L D Broekman, Steven De Vleeschouwer, Asgeir S Jakola, Martin J van den Bent, Susan M Chang, Michael A Vogelbaum, Arnaud J P E Vincent, Joerg-Christian Tonn, Mitchel S Berger
Topics: blood-cancer, brain-cancer, clinical-trials